Onconetix Financials - Benzinga

Onconetix Inc

ONCONASDAQ

Trade with Public

Trade with Public

$0.9249

-0.0951-9.32%

最終更新: Sep 8, 10:02 AM

概要ニュース業績予想財務センチメント株主構成比較株式レポート

Onconetix Financials

Onconetix (ONCO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?

Onconetix Inc. shares soared 23.65% after hours following clinical progress updates, new study initiation and developments in prostate cancer diagnostics.

Mohd Haider

PRO
Onconetix Q1 EPS $(6.71) Up From $(225.25) YoY, Sales $21.457K Down From $101.630K YoY

Onconetix (NASDAQ:ONCO) reported quarterly losses of $(6.71) per share. This is a 97.02 percent increase over losses of $(225.25) per share from the same period last year. The company reported $21.457 thousand in sales

Benzinga Newsdesk

PRO
Onconetix Q3 EPS $(6.25) Up From $(249.05) YoY, Sales $303.651K Down From $406.859K YoY

Onconetix (NASDAQ:ONCO) reported quarterly losses of $(6.25) per share. This is a 97.49 percent increase over losses of $(249.05) per share from the same period last year. The company reported $303.651 thousand in sales

Benzinga Newsdesk

PRO
Onconetix Q2 EPS $(4.76) Up From $(2.19 thousand) YoY, Sales $106.494K Down From $704.848K YoY

Onconetix (NASDAQ:ONCO) reported quarterly losses of $(4.76) per share. This is a 99.78 percent increase over losses of $(2.19 thousand) per share from the same period last year. The company reported $106.494 thousand

Benzinga Newsdesk

Dow Surges Over 100 Points; Goldman Sachs Posts Upbeat Earnings

Avi Kapoor

US Stocks Edge Higher; D.R. Horton Posts Upbeat Earnings

Avi Kapoor

© 2026 Benzinga | All Rights Reserved